Neurogene Inc. Stock price

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
50.9 USD +3.33% Intraday chart for Neurogene Inc. +13.62% +162.64%
Sales 2024 * - Sales 2025 * - Capitalization 654M
Net income 2024 * -61M Net income 2025 * -76M EV / Sales 2024 * -
Net cash position 2024 * 327M Net cash position 2025 * 501M EV / Sales 2025 * -
P/E ratio 2024 *
-13.6 x
P/E ratio 2025 *
-13.5 x
Employees 91
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.33%
1 week+13.62%
Current month+63.82%
1 month+56.91%
3 months+221.74%
Current year+162.64%
More quotes
1 week
46.69
Extreme 46.69
53.00
1 month
30.54
Extreme 30.54
53.00
Current year
19.00
Extreme 19
53.00
1 year
12.49
Extreme 12.49
53.00
3 years
12.49
Extreme 12.49
53.00
5 years
12.49
Extreme 12.49
53.00
10 years
12.49
Extreme 12.49
53.00
More quotes
Date Price Change Volume
24-03-28 50.9 +3.33% 411 713
24-03-27 49.26 -0.38% 139,979
24-03-26 49.45 +0.86% 80,599
24-03-25 49.03 -1.70% 211,713
24-03-22 49.88 +1.34% 215,801

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The Company is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The Company's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The Company is also developing NGN-101 for the treatment of CLN5 Batten disease. It is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
50.9 USD
Average target price
53.33 USD
Spread / Average Target
+4.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Neurogene Inc. - Nasdaq